Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

被引：1
|
作者：
Long, Georgina, V [1 ]
Luke, Jason J. [2 ]
Fukunaga-Kalabis, Mizuho [3 ]
Asierto, Paolo A. [4 ]
机构：
[1] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2060, Australia
[2] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Merck & Co Inc, Rahway, NJ USA
[4] Ist NazionaleTumori IRCCS Fdn Pascale, Naples, Italy
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 01期
关键词：
D O I：
10.1016/S1470-2045(22)00753-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E8 / E8
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14)
  • [2] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
    Long, G. V.
    Luke, J.
    Khattak, M. A.
    de la Cruz Merino, L.
    Del Vecchio, M.
    Rutkowski, P.
    Spagnolo, F.
    Mackiewicz, J.
    Chiarion-Sileni, V.
    Kirkwood, J. M.
    Robert, C.
    Grob, J. J.
    de Galitiis, F.
    Schadendorf, D.
    Carlino, M. S.
    Wu, L.
    Fukunaga-Kalabis, M.
    Krepler, C.
    Eggermont, A. M. M.
    Ascierto, P. A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 95 - 95
  • [3] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
    Long, Georgina V.
    Luke, Jason J.
    Khattak, Muhammad
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Larry
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M.
    Ascierto, Paolo Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [4] Phase III KEYNOTE-716 Study of Pembrolizumab (KEYTRUDA®) as adjuvant Therapy for Patients with resected Stage IIB or IIC Melanoma: significant Improvement in distant metastasis-free Survival versus Placebo
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [5] Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Khattak, Muhammad Adnan
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M. M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Larry
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [6] Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma
    Samlowski, Wolfram
    Silver, Michelle A.
    Hohlbauch, Andriana
    Zhang, Shujing
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Wang, Yunfei
    Sruti, Ila
    Jiang, Ruixuan
    [J]. MELANOMA RESEARCH, 2024, 34 (04) : 326 - 334
  • [7] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
    Long, Georgina, V
    Luke, Jason J.
    Khattak, Muhammad A.
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Mohr, Peter
    Dummer, Reinhard
    Gershenwald, Jeffrey E.
    Yoon, Charles H.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Ascierto, Paolo A.
    [J]. LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
  • [8] Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma
    Long, Georgina V.
    Gasal, Eduard
    Hauschild, Axel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (14): : 1374 - 1377
  • [9] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
    Favre-Bulle, Andrea
    Bencina, Goran
    Zhang, Shujing
    Jiang, Ruixuan
    Andritschke, Daniel
    Bhadhuri, Arjun
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
  • [10] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
12345